Antifungal treatment options in the critically ill patient;Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico

Revista Iberoamericana de Micologia

Volumn 29, Issue 2, 2012, Pages 108-113

  Zaragoza, Rafael ^a   Pemán, Javier ^b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antifungal treatment; Aspergillosis; Azoles; Deescalation therapy; Echinocandins; Invasive candidiasis; Polienes

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; VORICONAZOLE;

CANDIDA ALBICANS; CRITICALLY ILL PATIENT; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; INCIDENCE; INTENSIVE CARE; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LABORATORY TEST; MORBIDITY; MORTALITY; RISK REDUCTION; SHORT SURVEY; SYSTEMIC MYCOSIS;

ANTIFUNGAL AGENTS; CRITICAL ILLNESS; DECISION TREES; HUMANS; MYCOSES; PRACTICE GUIDELINES AS TOPIC;

CANDIDA ALBICANS;

EID: 84859042197     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2012.03.009     Document Type: Short Survey

References (56)

1. Aguado J.M., Ruiz-Camps I., Muñoz P., Mensa J., Almirante B., Vázquez L., et al. Recomendaciones sobre el tratamiento de la candidiasis invasiva yotras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) Actualización 2011. Enferm Infecc Microbiol Clin 2011, 29:345-361.
2. Alvarez-Lerma F., Nicolas-Arfelis J., Rodriguez-Borregan J., Diaz-Regañón J., Sa-Borges M., Garcia-Lopez F., et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005, 17:417-427.
3. Barrett J.P., Vardulaki K.A., Conlon C., Cooke J., Daza-Ramirez P., Evans E.G., et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003, 25:1295-1320.
4. Bergner R., Hoffmann M., Riedel K.D., Mikus G., Henrich D.M., Haefeli W.E., et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800mg. Nephrol Dial Transplant 2006, 21:1019-1123.
5. Carrillo-Muñoz A.J., Giusiano G., Ezkurra P.A., Quindós G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 2006, 19:130-139.
6. Cornely O.A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007, 60:363-369.
7. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
8. DiNubile M.J., Lupinacci R.J., Strohmaier K.M., Sable C.A., Kartsonis N.A. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007, 22:237-244.
9. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002, 49(Suppl 1):31-36.
10. Dupont B.F., Lortholary O., Ostrosky-Zeichner L., Stucker F., Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009, 13:R159.
11. Espinel-Ingroff A., Cantón E. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?. Enferm Infecc Microbiol Clin 2011, 29(Suppl 2):3-9.
12. Fluckiger U., Marchetti O., Bille J., Eggimann P., Zimmerli S., Imhof A., et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006, 136:447-463.
13. Fortún J., Carratalá J., Gavaldá J., Lizasoain M., Salavert M., De la Cámara R., et al. Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enferm Infecc Microbiol Clin 2011, 29:435-454.
14. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study. Clin Infect Dis 2006, 43:25-31.
15. GarnachoMontero J., León C., Almirante B., álvarezLerma F., CuencaEstrella M., GarcíaRodríguez J., et al. Recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico. Conferencia de consenso. Conclusiones. Med Intensiva 2005, 3(Suppl 3):43-52.
16. Guery B.P., Arendrup M.C., Auzinger G., Azoulay E., Borges S.M., Johnson E.M., et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment Intensive Care Med 2009, 35:206-214.
17. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
18. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
19. Ito J.I., Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005, 40(Suppl 6):S384-S391.
20. Kett D.H., Shorr A.F., Reboli A.C., Reisman A.L., Biswas P., Schlamm H.T. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011, 15:R253.
21. Kuhn D.M., George T., Chandra J., Mukherjee P.K., Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002, 46:1773-1780.
22. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
23. Kullberg B.J., Verweij P.E., Akova M., Arendrup M.C., Bille J., Calandra T., et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 2011, 17(Suppl 5):1-12.
24. Kuse E.R., Chetchotisakd P., Da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
25. Leroy O., Gangneux J.P., Montravers P., Mira J.P., Gouin F., Sollet J.P., et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618.
26. Limper A.H., Knox K.S., Sarosi G.A., Ampel N.M., Bennett J.E., Catanzaro A., et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011, 183:96-128.
27. Lutsar I., Roffey S., Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003, 37:728-732.
28. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
29. Marr K. Combination antifungal therapy: where are we now, and where are we going?. Oncology (Williston Park) 2004, 18:24-29.
30. Marr K.A., Boeckh M., Carter R.A., Kim H.W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
31. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
32. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
33. Muñoz P., Sanchez-Somolinos M., Alcala L., Rodriguez-Creixems M., Pelaez T., Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005, 55:188-193.
34. Ortega M., Marco F., Soriano A., Almela M., Martinez J.A., Lopez J., et al. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect 2011, 77:157-161.
35. Ortega M., Marco F., Soriano A., Almela M., Martinez J.A., Pitart C., et al. Candida spp. bloodstream infection: influence of antifungal treatment on outcome. J Antimicrob Chemother 2010, 65:562-568.
36. Ostrosky-Zeichner L., Oude Lashof A.M., Kullberg B.J., Rex J.H. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003, 22:651-655.
37. Pachón J., Cisneros J.M., Collado-Romacho A.R., Lomas-Cabezas J.M., Lozano dL-N., Parra-Ruiz J., et al. Tratamiento de las infecciones fúngicas invasivas. Enferm Infecc Microbiol Clin 2006, 24:254-263.
38. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
39. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
40. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
41. Pemán J., Cantón E., Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in. Spain Eur J Clin Microbiol Infect Dis 2005, 24:23-30.
42. Pemán J., Salavert M., Cantón E., Jarque I., Romá E., Zaragoza R., et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Management 2006, 2:1-30.
43. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., Dupont B., Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
44. Phillips P., Shafran S., Garber G., Rotstein C., Smaill F., Fong I., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997, 16:337-345.
45. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
46. Reboli A.C., Shorr A.F., Rotstein C., Pappas P.G., Kett D.H., Schlamm H.T., et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis 2011, 11:261.
47. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., Van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331:1325-1330.
48. Rodríguez-Tudela J.L., Almirante B., Rodríguez-Pardo D., Laguna F., Donnelly J.P., Mouton J.W., et al. Correlation of the MIC and Dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidaemia. Antimicrob Agents Chemother 2007, 51:3599-3604.
49. Shorr A.F., Lazarus D.R., Sherner J.H., Jackson W.L., Morrel M., Fraser V.J., et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007, 35:1077-1083.
50. Singh N., Limaye A.P., Forrest G., Safdar N., Munoz P., Pursell K., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320-326.
51. Troke P, Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, et al. Voriconazole (VCR) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il 476. 2003.
52. Vazquez J.A., Sobel J.D., Anidulafungin: a novel echinocandin. Clin Infect Dis 2006, 43:215-222.
53. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
54. Wingard J.R., Kubilis P., Lee L., Yee G., White M., Walshe L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29:1402-1407.
55. Zaragoza R., Luque P. Voriconazol en UCI: ¿cuáles son sus indicaciones, ventajas, precauciones y contraindicaciones reales?. Med Intensiva 2006, 4:S11-S18.
56. Zaragoza R., Pemán J. Diagnostic and therapeutic approach to fungal infections in critical care settings: different options but the same strategy. J Invasive Fungal Infect 2007, 1:50-58.